TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07751042: A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of STX-003 Delivered Intravenously in Patients With Advanced Solid Tumors

Sponsor: Strand Therapeutics Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07751042 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07751042 Rescue Dossier →